Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-α inhibitors in India - An audit report

Journal of Rheumatology

Volumn 36, Issue 7, 2009, Pages 1414-1420

  Malaviya, Anand N ^a,e   Kapoor, Sanjiv ^a   Garg, Shriram ^a   Rawat, Roopa ^a   Shankar, Subramanian ^b   Nagpal, Savita ^c   Khanna, Dinesh ^d   Furst, Daniel E ^d  

^a INDIAN SPINAL INJURIES CENTRE   (India)

^b Command Hospital ^*  (India)

^c Dr Savita Nagpal Laboratory   (India)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NONE

Author keywords

India; Inflammatory rheumatic diseases; Latent tuberculosis infection; Screening strategy; Tuberculosis infection; Tumor necrosis factor inhibitor

Indexed keywords

ETANERCEPT; ETHAMBUTOL; HYDROXYCHLOROQUINE; INFLIXIMAB; ISONIAZID; METHOTREXATE; METHYLPREDNISOLONE; PAMIDRONIC ACID; PREDNISOLONE; PYRAZINAMIDE; RIFAMPICIN; SALAZOSULFAPYRIDINE; THALIDOMIDE;

ADULT; AGED; ALERTNESS; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE EXACERBATION; DRUG TREATMENT FAILURE; FEMALE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; PREDICTION; PRIORITY JOURNAL; RHEUMATIC DISEASE; SCREENING TEST; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ANTITUBERCULAR AGENTS; CLINICAL AUDIT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; INDIA; MALE; MASS SCREENING; MIDDLE AGED; RADIOGRAPHY, THORACIC; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67650459132     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.081042     Document Type: Article

References (41)

1. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
2. Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004;39:1254-5.
3. Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006;43:717-22.
4. Keane J, Bresnihan B. Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies. Curr Opin Rheumatol 2008;20:443-9.
5. Report of the Meeting of the Expert Committee to Estimate TB Burden in India, 10-11th March 2005, New Delhi. [Internet. Accessed March 16, 2009.] Available from: http://www.tbcindia.org/Pdfs/TB%20burden%20consensus.pdf
6. Pathak SK, Deshmukh PA, Menon CRN. A comparison of different culture techniques. Indian J Tub 1973;20:85.
7. Hardas UD, Jayaram VS. Differential identification of mycobacteria. Indian J Tub 1984;31:11.
8. Paramasivan CN, Herbert D, Prabhakar R. Non-tuberculous mycobacteria: an overview. Lung India 1986;4:7-12.
9. Grover R, Kapoor S, Marwaha V, Malaviya AN, Gupta R, Kumar A. Clinical experience with infliximab in spondyloarthropathy: an open label study on fourteen patients. J Ind Rheumatol Assoc 2005;13:78-82.
10. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766-72.
11. Phadke MA, Kshirsagar NA. Blood tests for diagnosis of tuberculosis. Lancet 2006;368:282.
12. A joint statement. Targeted tuberculin testing and treatment of latent tuberculosis infection. Official statement of the American Thoracic Society (ATS), July 1999; A joint statement of ATS and the Centers for Disease Control and Prevention (CDC); Endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999. Am J Respir Crit Care Med 2000;161:S221-S247.
13. Mazurek GH, Jereb J, LoBue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the QuantiFERON® -TB Gold test for detecting Mycobacterium tuberculosis infection, United States. Centers for Disease Control and Prevention. MMWR Recomm Rep 2005;54:49-55.
14. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997;337:801-8.
15. Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 2007;45:715-22.
16. Blumberg HM. Needed: new and better tools to combat latent tuberculosis infection. Ann Intern Med 2008;149:761-3.
17. Chaturvedi V, Singal V, Marwaha V, et al. Use of infliximab in ankylosing spondylitis among young adults from Armed Forces in India [abstract]. In: Proceedings of the Asia Pacific League of Nations Against Rheumatic Diseases (APLAR) at Jeju Island, South Korea, 2004. APLAR abstract book 2004. Abstract no. 15, page 14.
18. Malaviya AN, Kapoor S, Garg S, Ahmad I, Raja RR. A new strategy of drug treatment in NSAID-unresponsive ankylosing spondylitis: combination of pamidronate and methylprednisolone monthly intravenous infusions on the background of a combination of disease modifying drugs sulfasalazine and methotrexate. J Assoc Physicians India 2007;55:193-7.
19. Gomez-Reino JJ, Carmona L, Angel DM. Risk of tuberculosis in patients treated with tumour necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007;57:756-61.
20. Huebner RE, Schein MF, Bass JB Jr. The tuberculin skin test. Clin Infect Dis 1993;17:968-75.
21. Palit J, Chattopadhyay C, Malaviya AN, Uberoi S, Kumar R. Some immunological parameters in rheumatoid arthritis from India. Biomedicine 1977;27:70-3.
22. Ponce dL, Acevedo-Vasquez E, Sanchez-Torres A, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005;64:1360-1.
23. Ferrara G, Losi M, D'Amico R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006;367:1328-34.
24. Markusse HM, Hazes JM, Dijkmans BA, de Vries RR, Stanford JL. Skin test responsiveness to Mycobacterium tuberculosis, HLA-DR4, and rheumatoid arthritis. Ann Rheum Dis 1989;48:175-6.
25. Matulis G, Juni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon (gamma) assay. Ann Rheum Dis 2008;67:84-90.
26. de Leon DP, Vasquez AE, Alvizuri S, et al. Comparison of an interferon-γ assay with tuberculin skin testing for detection of tuberculosis (TB) in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008;35:776-81.
27. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR Recomm Rep 1996;45:1-18.
28. CDC - Division of Tuberculosis Elimination (DTBE) Fact Sheets; April 2006. [Internet. Accessed March 16, 2009.] Available from: http://www.cdc.gov/ tb/pubs/tbfactsheets/BCG.htm
29. Expanded programme on immunization (EPI). Immunization schedules in the WHO South-East Asia region, 1995. Wkly Epidemiol Rec 1996;71:100-2.
30. Chadha VK, Jagannatha PS, Kumar P. Can BCG-vaccinated children be included in tuberculin surveys to estimate the annual risk of tuberculous infection in India? Int J Tuberc Lung Dis 2004;8:1437-42.
31. Gustafson P, Lisse I, Gomes V, et al. Risk factors for positive tuberculin skin test in Guinea-Bissau. Epidemiology 2007;18:340-7.
32. Tissot F, Zanetti G, Francioli P, Zellweger JP, Zysset F. Influence of bacille Calmette-Guerin vaccination on size of tuberculin skin test reaction: to what size? Clin Infect Dis 2005;40:211-17.
33. Mazurek GH, LoBue PA, Daley CL, et al. Interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 2001;286:1740-47.
34. Pai M, Zwerling A, Menzies D. Systematic review: T-cell based assays for the diagnosis of latent tuberculosis infection: An update. Ann Intern Med 2008;149:177-84.
35. Richeldi L. An update on the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 2006;174:736-42.
36. Food and Drug Administration, Center for Devices and Radiological Health. Summary of safety and effectiveness data. QuantiFERON-TB. PMA no. P010033. Rockville, MD: Food and Drug Administration; 2002. [Internet. Accessed March 19, 2009.] Available from: http://www.fda.gov/cdrh/pdf/P010033b.pdf
37. Greenberg JD, Reddy SM, Schloss SG, et al. Comparison of an in vitro tuberculosis interferon-gamma assay with delayed-type hypersensitivity testing for detection of latent Mycobacterium tuberculosis: A pilot study in rheumatoid arthritis. J Rheumatol 2008;35:770-5.
38. Chen D-Y, Shen G-H, Hsieh T-Y, Hsieh C-W, Lanan J-L. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Care Res 2008;59:800-6.
39. Barnes PF. Weighing gold or counting spots. Which is more sensitive to diagnose latent tuberculosis infection? Am J Respir Crit Care Med 2006;174:731-2.
40. National Collaborating Centre for Chronic Diseases. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: Royal College of Physicians; 2006.
41. Canadian Tuberculosis Committee. Interferon gamma release assays for latent tuberculosis infection. Canada Communicable Disease Report (CCDR) 2007. ACS 10; 1 Nov 2007. [Internet. Accessed March 16, 2009.] Available from: http://www.phac-aspc.gc.ca/ publicat/ccdr-rmtc/07vol33/